Keros Therapeutics Stock Today
| KROS Stock | USD 53.84 0.30 0.55% |
Performance8 of 100
| Odds Of DistressLess than 9
|
Keros Therapeutics is selling for under 53.84 as of the 22nd of November 2024; that is 0.55 percent decrease since the beginning of the trading day. The stock's lowest day price was 53.09. Keros Therapeutics has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for Keros Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of April 2020 | Category Healthcare | Classification Health Care |
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company has 40.51 M outstanding shares of which 2.41 M shares are now shorted by private and institutional investors with about 7.8 trading days to cover. More on Keros Therapeutics
Moving together with Keros Stock
Moving against Keros Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Keros Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsKeros Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Keros Therapeutics' financial leverage. It provides some insight into what part of Keros Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Keros Therapeutics (KROS) is traded on NASDAQ Exchange in USA. It is located in 1050 Waltham Street, Lexington, MA, United States, 02421 and employs 160 people. Keros Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.19 B. Keros Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 40.51 M outstanding shares of which 2.41 M shares are now shorted by private and institutional investors with about 7.8 trading days to cover.
Keros Therapeutics currently holds about 215.62 M in cash with (124.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.37.
Check Keros Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Keros Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Keros Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Keros Therapeutics. Please pay attention to any change in the institutional holdings of Keros Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Keros Ownership Details
Keros Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Nantahala Capital Management, Llc | 2024-06-30 | 757.6 K | |
| Braidwell Lp | 2024-09-30 | 707.2 K | |
| Holocene Advisors, Lp | 2024-06-30 | 688.3 K | |
| Geode Capital Management, Llc | 2024-06-30 | 679.6 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 671.3 K | |
| Redmile Group, Llc | 2024-09-30 | 552.5 K | |
| Adar1 Capital Management Llc | 2024-06-30 | 548.9 K | |
| Paradigm Biocapital Advisors Lp | 2024-09-30 | 525 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 521.4 K | |
| Fmr Inc | 2024-09-30 | 4.9 M | |
| Blackrock Inc | 2024-06-30 | 2.5 M |
Keros Therapeutics Historical Income Statement
Keros Stock Against Markets
Keros Therapeutics Corporate Management
| Robin Wagner | Senior Resources | Profile | |
| Simon MBBS | Chief Officer | Profile | |
| Keith MBA | Chief Officer | Profile | |
| Christopher MSc | Chief Officer | Profile | |
| John MBA | Senior Management | Profile | |
| Jennifer Lachey | Chief Officer | Profile | |
| Jasbir Seehra | CEO and President | Profile |
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.